OR WAIT null SECS
May 15, 2026
Video
Marc Ruel, MD, MPH, discusses the progress made since in the 11 years since the last guidelines, both in treatment and therapy.
May 10, 2026
Saseen discusses the current dyslipidemia treatment landscape, highlighting current challenges and potential paths forward.
May 05, 2026
Blaha discusses his study analyzing nonstatin prescriptions from 2019-2024, highlighting the need for further clinical implementation of modern guidelines.
April 09, 2026
Catapano discusses the superior reduction in LDL-C, ApoB, and non-HDL-C demonstrated by enlicitide, suggesting its role as an add-on for LDL-C lowering.
Article
Catch up on major trial results, groundbreaking guideline updates, and more.
April 08, 2026
March 2026 cardiology updates feature key ACC.26 data, new guidelines, and advances in PAH, AF, hypertension, and lipid management.
April 07, 2026
Navar discusses the phase 3 CORALreef AddOn trial, highlighting enlicitide’s superiority to ezetimibe, bempedoic acid, and a combination of both.
April 03, 2026
Catch up on the most impactful trial readouts to come out of ACC 2026.
April 02, 2026
Nicholls discusses his recent pooled analysis of safety data from the BROADWAY and BROOKLYN phase 3 trials, proving the tolerable safety of obicetrapib.
March 28, 2026
A subgroup analysis of VESALIUS-CV suggests evolocumab could have a role in prevention of primary events in some high-risk patients.
